#hepatocellular carcinoma

Results in cell and mouse studies may have implications for the development of a new class of anticancer drugs.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.

October is Liver Cancer Awareness Month.

Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.

People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.

However, people with liver cirrhosis remain at risk and should continue screening even after being cured.

Second- and third-generation individuals in Los Angeles had a 35% and 61% higher risk, respectively, than those born in Mexico.

The risk of HCC fell further as cumulative antihistamine use rose in people with HBV, HCV or both.

A liver transplant may still be a viable option for older people with liver cancer.

Liver cancer is now less likely to be caused by hepatitis B or C, but more likely to be caused by fatty liver disease or alcohol.

People who developed hepatocellular carcinoma after being cured of HCV had cirrhosis and worse liver function.

More than a third of hepatocellular carcinoma cases among Medicare recipients were due to fatty liver disease.

Cases of the most common type of liver cancer, hepatocellular carcinoma, are on the rise.